This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Zor Pharmaceuticals LLC
Drug Names(s): Virulizin
Description: Virulizin is a novel biological response modifier (BRM), derived from bovine bile, that enhances cell-mediated immune response to tumour cells by direct macrophage activation.
Preclinical and early clinical trial evidence of Virulizin’s ability to enhance the anti-cancer activities of surveillance cells such as natural killer cells and macrophages is compelling, but data regarding clinical endpoints are immature. Virulizin is marketed in Mexico for malignant melanoma.
Deal Structure: In April 2008, Lorus Therapeutics announced that it signed an exclusive multinational license agreement with Zor Pharmaceuticals LLC, formed as a subsidiary of Zoticon Bioventures, to further develop and commercialize Virulizin for human therapeutic applications. The initial clinical development of Virulizin under the agreement will be in advanced pancreatic cancer.
Zor Pharmaceuticals will be responsible for the cost of all the clinical development, regulatory submissions and commercialization of Virulizin in North and South America and Europe. Lorus will retain rights in all other countries, including Japan, Australia and New Zealand.
In October 2008, Lorus announced that Central America has been added to the territories covered in the exclusive licensing agreement with Zor Pharmaceuticals. Due to the extension of the agreement, Lorus will receive an additional US 2 million dollars upon achievement of specific developmental and sales milestones in addition to royalties on sales.
Partners: Aptose Biosciences Inc.
Pink Sheet Lorus Virulizin pancreatic cancer data
Pink Sheet Pancreatic Cancer Drugs In Development
Additional information available to subscribers only: